Disease Landscape and Forecast 인사이트

Clarivate Epidemiology’s coverage of obesity / overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of obesity /…

Clarivate Epidemiology’s coverage of obesity / overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of obesity /…

Clarivate Epidemiology’s coverage of obesity / overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of obesity /…

Clarivate Epidemiology’s coverage of obesity / overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total obesity / overweight…

The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.), which…

Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…

The treatment of ovarian cancer has been transformed by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (Zejula; GSK), and…

The urticaria drug market is dominated by oral medications—including steroids and second-generation, nondrowsy antihistamines—which are prescribed for both chronic inducible urticaria (CIndU)…

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs or systems in the body. The treatment goals of physicians who manage SLE patients differ depending on…

The advent of Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) has revolutionized the treatment of gastroesophageal cancer, leading to substantial growth of this…

The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. In the last 30 years, only two immunotherapies have been approved in this indication:…

Market outlookAlzheimer’s disease (AD) is a progressive and irreversible brain disorder that leads to a decline in cognitive abilities, affecting memory and causing patients’ quality of life to…